'Innovation' Meeting Shows FDA-Industry Gap On NDI Guidance Details Remains
Executive Summary
Panel discussions and public comments during FDA public meeting show industry sees agency, as it stated in draft NDI notification guidances published in 2011 and 2016, is allowing little room for innovation through making new ingredients available for use in VMS products. FDA says immense growth of the VMS market since DSHEA passed shows numerous products available in US contain substances that haven't been notified to the FDA with proof showing they are dietary ingredients and are safe for use.
You may also be interested in...
CHPA Adds Pavlick, Miller In Director Posts
Larisa Pavlick joins senior director of quality assurance and technical affairs, and Kirby Miller as director of federal government affairs.
NDI Notification Guidance Deadline Included In Senate Draft Bill For FDA User Fee Programs
HELP Committee Chairwoman Patty Murray, and ranking member Richard Burr also include supplement registration requirement in discussion draft for reauthorizing FDA’s user fee programs for prescription, generic and biosimilar drugs and medical devices.
Comments On Petition As Good As Public Hearing On NAC’s Use As Dietary Ingredient – US FDA
Agency "does not believe a hearing is necessary at this time given the other mechanisms at stakeholders’ disposal to interact with FDA on this issue, including submission of comments" for citizen petition CRN submitted on NAC, Andrew Tantillo, acting associate commissioner for legislative affairs, tells Sen. Mike Lee.